论文部分内容阅读
目的评价罗红霉素缓释片治疗Ⅰ型慢性鼻窦炎的疗效及安全性。方法 366例Ⅰ型慢性鼻窦炎患者随机双盲分为两组:A组,186例,口服罗红霉素缓释片300 mg,每天1次;B组,180例,口服罗红霉素片300 mg,每天1次,作为对照。疗程8周。比较两组疗效及不良反应。结果 A、B两组有效率相仿(87.63%vs.86.11%);A组不良反应发生率显著低于B组(4.62%vs.13.46%)(P<0.01)。结论罗红霉素缓释片治疗Ⅰ型慢性鼻窦炎安全、有效。
Objective To evaluate the efficacy and safety of roxithromycin sustained-release tablets in the treatment of type Ⅰ chronic sinusitis. Methods 366 patients with type Ⅰ chronic sinusitis were randomly divided into two groups: group A, 186 patients, oral roxithromycin sustained-release tablets 300 mg once daily; group B, 180 patients, oral roxithromycin tablets 300 mg once daily as a control. Treatment for 8 weeks. The curative effect and adverse reaction of two groups were compared. Results The effective rates of A and B groups were similar (87.63% vs.86.11%). The incidence of adverse reactions in group A was significantly lower than that in group B (4.62% vs.13.46%, P <0.01). Conclusion Roxithromycin sustained-release tablets in the treatment of type Ⅰ chronic sinusitis is safe and effective.